Core Viewpoint - The National Healthcare Security Administration (NHSA) has released the 11th batch of centralized drug procurement documents, introducing optimized price difference control mechanisms to ensure fairness and prevent abnormal low pricing from distorting the market [1] Group 1: Price Control Mechanisms - The new procurement process will continue to control the price differences for selected drugs, rather than simply adopting the lowest bid [1] - If the lowest bid is below 50% of the average winning price, the price difference control will be anchored at 50% of the average winning price [1] - This adjustment aims to mitigate the risk of "price wars" among companies, effectively raising the average price for about 25% of the products that would have triggered an increase in the price control anchor [1] Group 2: Impact of Price Adjustments - In cases where the highest bid is more than 1.8 times the lowest bid, the average price is expected to increase by an average of 34%, with some products seeing increases as high as 170% [1] - These measures are designed to counteract excessive competition and stabilize the pricing environment for pharmaceuticals [1]
国家医保局：本次集采优化了价差控制“锚点”的选择，不再简单选用最低报价
Bei Jing Shang Bao·2025-09-20 08:14